Quarterly ResultAug 12, 2026, 04:07 PM
SeaStar Medical Q2 Revenue +82% to $0.6M; Adult AKI Trial Advances
AI Summary
SeaStar Medical reported Q2 2026 net revenue of $0.6 million, an 82% increase year-over-year, driven by expanded use of its QUELIMMUNE therapy in pediatric acute kidney injury (AKI). The company also significantly advanced enrollment in its NEUTRALIZE-AKI pivotal clinical trial for adult AKI patients, reaching 223 of 339 patients. Additionally, SeaStar Medical obtained ICD-10-PCS codes for its Selective Cytopheretic Device (SCD) therapy, enabling standardized inpatient hospital billing. The net loss for the quarter was $3.7 million.
Key Highlights
- QUELIMMUNE Q2 2026 net revenue increased 82% to $0.6 million.
- Added 3 top-rated children's hospitals for QUELIMMUNE, totaling 20 customers.
- NEUTRALIZE-AKI adult trial enrolled 223 of 339 patients.
- Obtained ICD-10-PCS codes for SCD therapy, effective October 1, 2026.
- Q2 2026 net loss was $3.7 million, or $0.91 per share.
- Research and development expenses increased to $2.5 million from $1.0 million.
- Cash balance at June 30, 2026, was $7.0 million.
Price Impact
More from ICU